Provided by Tiger Trade Technology Pte. Ltd.

TransCode Therapeutics Inc.

8.91
-1.0600-10.63%
Post-market: 8.56-0.3500-3.93%19:59 EST
Volume:161.96K
Turnover:1.45M
Market Cap:8.17M
PE:-0.04
High:10.08
Open:9.89
Low:7.99
Close:9.97
52wk High:357.56
52wk Low:6.08
Shares:916.97K
Float Shares:832.40K
Volume Ratio:0.07
T/O Rate:19.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-236.5200
EPS(LYR):-1,317.4218
ROE:-1763.01%
ROA:-232.54%
PB:5.73
PE(LYR):-0.01

Loading ...

Top Midday Gainers

MT Newswires Live
·
Feb 06

TransCode Therapeutics Advances Phase 2a Colorectal Cancer Trial

TIPRANKS
·
Feb 05

Transcode Therapeutics, Quantum Leap submit IND for Phase 2a trial of TTX-MC138

TIPRANKS
·
Feb 05

TransCode Therapeutics Submits IND Amendment for Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Reuters
·
Feb 05

Transcode Therapeutics and Quantum Leap Announce Submission of Ind Amendment for Phase 2a Clinical Trial With Ttx-Mc138

THOMSON REUTERS
·
Feb 05

BRIEF-Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026

Reuters
·
Jan 06

Transcode Therapeutics Inc - Ttx-Mc138 Phase 2a Clinical Trial Expected in First Half of 2026 - SEC Filing

THOMSON REUTERS
·
Jan 06

TransCode Therapeutics Reports Preclinical Success of TTX-MC138 in Glioblastoma Models

Reuters
·
Jan 06

TransCode Therapeutics Files Amended 8-K on ABCJ Acquisition

Reuters
·
Dec 24, 2025

Transcode Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Jack E. Stover

Reuters
·
Dec 23, 2025

Transcode Therapeutics Expands Leadership With Appointment of Jack E. Stover to Board of Directors

THOMSON REUTERS
·
Dec 22, 2025

Press Release: TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

Dow Jones
·
Dec 22, 2025

Transcode Therapeutics Inc Files for Mixed Shelf of up to $150 Mln – SEC Filing

THOMSON REUTERS
·
Dec 13, 2025

TransCode Therapeutics and Quantum Leap Launch Phase 2a Trial for TTX-MC138 in Colorectal Cancer

Reuters
·
Dec 11, 2025

Transcode Therapeutics Inc - Phase 2a Trial to Begin in 2026

THOMSON REUTERS
·
Dec 11, 2025

BRIEF-Transcode Therapeutics Expands Executive Team With Appointment Of Dr. Michel Janicot As Senior Development Officer

Reuters
·
Nov 17, 2025

Transcode Therapeutics Expands Executive Team With Appointment of DR. Michel Janicot as Senior Development Officer

THOMSON REUTERS
·
Nov 17, 2025

Press Release: TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

Dow Jones
·
Nov 17, 2025

TransCode Therapeutics Amends Preferred Stock Designation

TIPRANKS
·
Oct 27, 2025

TransCode Therapeutics Updates SEC Filing to Report CVR Agreement Effective Date and Change in Rights Agent

Reuters
·
Oct 18, 2025